gp96 antigen peptide complex sensitized dendritic cells

Dendritic cells sensitized with gp96 antigen peptide complexes are a form of personalized cell-based immunotherapy. In this approach, dendritic cells (DCs)—potent antigen-presenting immune cells—are pulsed or loaded ex vivo with complexes of heat shock protein gp96 and tumor-derived peptides. Gp96 acts as a natural adjuvant and chaperone for tumor-specific antigens, facilitating their uptake and presentation by DCs through specific receptors. Once matured and re-infused into the patient, these DCs stimulate robust T cell responses—including cytotoxic T lymphocytes (CTLs) that specifically target cancer cells expressing the relevant antigens. This strategy has been investigated in preclinical models for various cancers such as hepatocellular carcinoma and gastric cancer, where it enhances DC maturation (upregulating MHC class II, CD80/86/40/83), promotes cytokine secretion (e.g., IL-12, IFN-γ), increases proliferation of autologous T lymphocytes and NK cell activity, and induces MHC class I-restricted CTL-mediated killing of tumor cells[1][2][3]. The therapy is considered a promising immunotherapeutic approach for generating anti-tumor immunity using patient-specific tumor antigens.

Other names

gp96-peptide complex pulsed dendritic cellsgp-96-peptide complex pulsed dendritic cellsgp 96-peptide complex pulsed dendritic cellsHSP-gp96 peptide complex loaded dendritic cellsHSP-gp-96 peptide complex loaded dendritic cellsHSP-gp 96 peptide complex loaded dendritic cellsgp96-DC vaccinegp-96-DC vaccinegp 96-DC vaccine